文献速递心脏核医学神经核医学

缺血性室速基质的区域异质性:CMR瘢痕、123I-MIBG SPECT与双极电压标测对比

Ventricular Tachycardia (VT) Substrate Characteristics: Insights from Multimodality Structural and Functional Imaging of the VT Substrate Using Cardiac MRI Scar, 123I-Metaiodobenzylguanidine SPECT Innervation, and Bipolar Voltage.
PubMed 文献 · J Nucl Med · 2018-06-29

15例缺血性心肌病合并药物难治性室速患者接受晚期钆增强心脏MRI、123I-间碘苄胍SPECT和高分辨率双极电压标测,比较瘢痕、异常神经支配和低电压区的范围。三种模态所示异常区域大小相似,但任一单模态均低估总室速基质面积。全部14个室速通道/出口位点均位于同时存在CMR瘢痕和异常神经支配的心肌。

要点

  • 任一单模态均低估总室速基质面积(P<0.001)。
  • 全部14个室速通道/出口位点均位于CMR瘢痕合并异常神经支配区。
  • CMR瘢痕合并异常神经支配区占CMR瘢痕的68.3%、总异常基质的31.2%。

核心结论

  • 结构和功能成像显示缺血后室速基质存在区域异质性,任何单一模态均无法单独识别。
  • 异常神经支配与CMR瘢痕共存可能识别一种尤其「致心律失常」的适应,并可能代表室速消融的潜在新靶点。

研究设计与样本

  • 15例缺血性心肌病合并药物难治性室速患者接受晚期钆增强心脏MRI、123I-间碘苄胍SPECT和高分辨率双极电压标测。
  • 分别以>3 SDs定义瘢痕、<50%示踪剂摄取定义异常神经支配、<1.5 mV定义低电压区。
  • 三维重建的CMR和123I-间碘苄胍模型进行配准比较。

主要发现

  • CMR瘢痕面积为46.1 cm2(33.1-86.9 cm2),异常神经支配面积为47.8 cm2(40.5-68.1 cm2),低电压区面积为29.5 cm2(24.5-102.6 cm2),三者比较P>0.05。
  • 任一单模态均低估总室速基质面积(定义为三种模态中至少一种异常的面积),总室速基质面积为76.0 cm2(57.9-143.2 cm2),P<0.001。
  • 总室速基质区内,三种模态均异常的区域最常见(25.2%)。
  • 异质性适应区域中,最常见的类别为「仅异常神经支配」(18.2%)、「仅CMR瘢痕合并异常神经支配」(14.9%)和「仅CMR瘢痕」(14.6%)。
  • 全部14个室速通道/出口位点(0.88 ± 0.74 mV)均位于同时显示CMR瘢痕和异常神经支配的心肌,该特定组织类别占CMR瘢痕的68.3%和总异常缺血后室速基质面积的31.2%。

关键数值与推荐

  • CMR瘢痕定义为晚期钆增强>3 SDs。
  • 异常神经支配定义为123I-间碘苄胍示踪剂摄取<50%。
  • 低电压区定义为双极电压<1.5 mV。
  • 总室速基质面积定义为三种模态中至少一种异常的面积。

临床怎么用

  • 结构和功能成像联合可识别缺血后室速基质的区域异质性。
  • 异常神经支配与CMR瘢痕共存可能识别尤其「致心律失常」的适应,并可能代表室速消融的潜在新靶点。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Postischemic adaptation results in characteristic myocardial structural and functional changes in the ventricular tachycardia (VT) substrate. The aim of this study was to compare myocardial structural and functional adaptations (late gadolinium enhancement/abnormal innervation) with detailed VT mapping data to identify regional heterogeneities in postischemic changes. Methods: Fifteen patients with ischemic cardiomyopathy and drug-refractory VT underwent late gadolinium enhancement cardiac MRI (CMR), 123I-metaiodobenzylguanidine SPECT, and high-resolution bipolar voltage mapping to assess fibrosis (>3 SDs), abnormal innervation (<50% tracer uptake), and low-voltage area (<1.5 mV), respectively. Three-dimensional reconstructed CMR/123I-metaiodobenzylguanidine models were coregistered for further comparison. Results: Postischemic structural and functional adaptations in all 3 categories were similar in size (reported as median [quartile 1-quartile 3]: CMR scar, 46.1 cm2 [33.1-86.9 cm2]; abnormal innervation, 47.8 cm2 [40.5-68.1 cm2]; and low-voltage area, 29.5 cm2 [24.5-102.6 cm2]; P > 0.05). However, any single modality underestimated the total VT substrate area defined as abnormal in at least 1 of the 3 modalities (76.0 cm2 [57.9-143.2 cm2]; P < 0.001). Within the total VT substrate area, regions abnormal in all 3 modalities were most common (25.2%). However, significant parts of the VT substrate had undergone heterogeneous adaptation (abnormal in <3 modalities); the most common categories were "abnormal innervation only" (18.2%), "CMR scar plus abnormal innervation only" (14.9%), and "CMR scar only" (14.6%). All 14 VT channel/exit sites (0.88 ± 0.74 mV) were localized to myocardium demonstrating CMR scar and abnormal innervation. This specific tissue category accounted for 68.3% of the CMR scar and 31.2% of the total abnormal postischemic VT substrate area. Conclusion: Structural and functional imaging demonstrated regional heterogeneities in the postischemic VT substrate not appreciated by any single modality alone. The coexistence of abnormal innervation and CMR scar may identify a particularly "proarrhythmic" adaptation and may represent a potential novel target for VT ablation.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Imanli H, Ume KL, Jeudy J, et al. Ventricular Tachycardia (VT) Substrate Characteristics: Insights from Multimodality Structural and Functional Imaging of the VT Substrate Using Cardiac MRI Scar, 123I-Metaiodobenzylguanidine SPECT Innervation, and Bipolar Voltage. J Nucl Med. 2018. PMID: 29959218. doi:10.2967/jnumed.118.211698

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。